In the trial, doses ranging from 0.5mg to 0.9mg of ALG-055009 led to notable median relative reductions in liver fat.

Increased funding and new public health policies for sickle cell research are needed to ease the burden on low-income nations ...

AstraZeneca's take on the PCSK9 inhibitor – an antisense drug licensed from Ionis six years ago – has cleared a proof-of-concept trial in high-risk patients with high blood cholesterol ...

Sarepta's Elevidys approval, revenue growth projections, and competitive position make it a strong investment in DMD ...

Denali reports new method to get antisense oligonucleotides across blood-brain barrier Recent years have seen a boom in ...

Biogen BIIB announced positive initial data from the pivotal cohort (Part B) of its mid to late-stage study evaluating the ...

Several ASX companies are conducting clinical trials, and this has become a valuable sector and an asset to the Australian ...

AcuraStem has received $4 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance the ...

Here we report the use of C5-propynyl-dU,dC-phosphorothioate antisense oligonucleotides to inhibit IGF-I receptor expression in keratinocytes. We identified several inhibitory antisense ...

Clinical decision-making can be difficult for patients with SMA due to the lack of clinical trials comparing treatment ...

Learn more about whether ACADIA Pharmaceuticals Inc or Centessa Pharmaceuticals PLC - ADR is a better investment based on ...